Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA New Drug Approval Count May Fall Back To Earth In 2016

Executive Summary

A repeat of FDA’s record-breaking NME approval performance from recent years looks unlikely, even though the 14 novel approvals in the first half of 2016 equals the first half total for 2015, because almost one-third fewer novel candidates have user fee goals in the second half.

Advertisement

Related Content

Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
User Fee Extensions Are Key To CDER's First Cycle Review Success
NME Half-Year Report: CDER Sets Strong Foundation With 14 Novel Approvals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel